纯化灭活寨卡病毒候选疫苗在美国经日本脑炎病毒或黄热病毒疫苗预免疫成人中的安全性和免疫原性:一项1期、随机、双盲、安慰剂对照临床试验
这项1期随机双盲安慰剂对照试验在美国招募75名黄病毒naive成人,按1:1:1分为无预免疫、日本脑炎疫苗(IXIARO)预免疫或黄热疫苗(YF-VAX)预免疫组,再按4:1随机接受ZPIV或安慰剂。ZPIV耐受性良好,但免疫原性随既往黄病毒疫苗接种状态显著不同,第三剂ZPIV可克服大部分但非全部免疫原性差异。
要点
- ZPIV在黄病毒naive和预免疫成人中耐受性良好,仅注射部位疼痛在ZPIV组更常见。
- 第57天黄病毒naive组血清转化率88%,日本脑炎疫苗预免疫组31.6%,黄热疫苗预免疫组25%。
- 第三剂ZPIV后血清转化率分别升至100%、92.9%和60%,GMT分别为511.5、174.2和79。
核心结论
- ZPIV在黄病毒naive和预免疫成人中耐受性良好,但免疫原性随既往黄病毒疫苗接种状态显著变化;第三剂ZPIV可克服大部分但非全部免疫原性差异。
研究设计与样本
- 1期、随机、双盲、安慰剂对照临床试验,在美国马里兰州银泉市沃尔特·里德陆军研究所临床试验中心进行。
- 招募75名18-49岁健康成人,无既往黄病毒暴露证据,按1:1:1序贯入组接受无预免疫、两剂肌肉注射日本脑炎病毒疫苗(IXIARO)或单剂皮下注射黄热病毒疫苗(YF-VAX)。
- 各组内按4:1随机接受肌肉注射ZPIV或安慰剂,预免疫接种在ZPIV前72-96天给予,ZPIV在第0、28和196-234天给予两或三次。
- 主要结局为征集性全身和局部不良事件及严重不良事件和特殊关注不良事件的发生率,在所有接受至少一剂ZPIV或安慰剂者中分析。
主要发现
- 2016年11月7日至2018年10月30日评估134名参与者资格,75名招募并随机分配,其中男性35名(47%),女性40名(53%)。
- 注射部位疼痛是唯一在ZPIV组比安慰剂组报告更频繁的不良事件(ZPIV组39/60例,65%,95%CI 51.6-76.9 vs 安慰剂组3/14例,21.4%,95%CI 4.7-50.8;p=0.006)。
- 第57天,黄病毒naive组血清转化率88%(95%CI 63.6-98.5,15/17),GMT 100.8(39.7-255.7);日本脑炎疫苗预免疫组血清转化率31.6%(95%CI 12.6-56.6,6/19),GMT 11.8(6.1-22.8);黄热疫苗预免疫组血清转化率25%(95%CI 8.7-49.1,5/20),GMT 6.6(5.2-8.4)。
- 第三剂ZPIV后,黄病毒naive组、日本脑炎疫苗预免疫组和黄热疫苗预免疫组的血清转化率分别为100%(95%CI 69.2-100,10/10)、92.9%(95%CI 66.1-99.8,13/14)和60%(95%CI 32.2-83.7,9/15),GMT分别为511.5(177.6-1473.6)、174.2(51.6-587.6)和79(19.0-326.8)。
临床怎么用
- 作者认为,这些1期临床试验结果对进一步评估ZPIV的免疫接种方案和联合接种的使用具有意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Zika virus infection is a threat to at-risk populations, causing major birth defects and serious neurological complications. Development of a safe and efficacious Zika virus vaccine is, therefore, a global health priority. Assessment of heterologous flavivirus vaccination is important given co-circulation of Japanese encephalitis virus and yellow fever virus with Zika virus. We investigated the effect of priming flavivirus naive participants with a licensed flavivirus vaccine on the safety and immunogenicity of a purified inactivated Zika vaccine (ZPIV). METHODS: This phase 1, placebo-controlled, double-blind trial was done at the Walter Reed Army Institute of Research Clinical Trials Center in Silver Spring, MD, USA. Eligible participants were healthy adults aged 18-49 years, with no detectable evidence of previous flavivirus exposure (by infection or vaccination), as measured by a microneutralisation assay. Individuals with serological evidence of HIV, hepatitis B, or hepatitis C infection were excluded, as were pregnant or breastfeeding women. Participants were recruited sequentially into one of three groups (1:1:1) to receive no primer, two doses of intramuscular Japanese encephalitis virus vaccine (IXIARO), or a single dose of subcutaneous yellow fever virus vaccine (YF-VAX). Within each group, participants were randomly assigned (4:1) to receive intramuscular ZPIV or placebo. Priming vaccinations were given 72-96 days before ZPIV. ZPIV was administered either two or three times, at days 0, 28, and 196-234. The primary outcome was occurrence of solicited systemic and local adverse events along with serious adverse events and adverse events of special interest. These data were analysed in all participants receiving at least one dose of ZPIV or placebo. Secondary outcomes included measurement of neutralizing antibody responses following ZPIV vaccination in all volunteers with available post-vaccination data. This trial is registered at ClinicalTrials.gov, NCT02963909. FINDINGS: Between Nov 7, 2016, and Oct 30, 2018, 134 participants were assessed for eligibility. 21 did not meet inclusion criteria, 29 met exclusion criteria, and ten declined to participate. 75 participants were recruited and randomly assigned. 35 (47%) of 75 participants were male and 40 (53%) were female. 25 (33%) of 75 participants identified as Black or African American and 42 (56%) identified as White. These proportions and other baseline characteristics were similar between groups. There were no statistically significant differences in age, gender, race, or BMI between those who did and did not opt into the third dose. All participants received the planned priming IXIARO and YF-VAX vaccinations, but one participant who received YF-VAX dropped out before receipt of the first dose of ZPIV. 50 participants received a third dose of ZPIV or placebo, including 14 flavivirus-naive people, 17 people primed with Japanese encephalitis virus vaccine, and 19 participants primed with yellow fever vaccine. Vaccinations were well tolerated across groups. Pain at the injection site was the only adverse event reported more frequently in participants who received ZPIV than in those who received placebo (39 [65%] of 60 participants, 95% CI 51·6-76·9 who received ZPIV vs three [21·4%] of 14 who received placebo; 4·7-50·8; p=0·006). No patients had an adverse event of special interest or serious adverse event related to study treatment. At day 57, the flavivirus-naive volunteers had an 88% (63·6-98·5, 15 of 17) seroconversion rate (neutralising antibody titre ≥1:10) and geometric mean neutralising antibody titre (GMT) against Zika virus of 100·8 (39·7-255·7). In the Japanese encephalitis vaccine-primed group, the day 57 seroconversion rate was 31·6% (95% CI 12·6-56·6, six of 19) and GMT was 11·8 (6·1-22·8). Participants primed with YF-VAX had a seroconversion rate of 25% (95% CI 8·7-49·1, five of 20) and GMT of 6·6 (5·2-8·4). Humoral immune responses rose substantially following a third dose of ZPIV, with seroconversion rates of 100% (69·2-100; ten of ten), 92·9% (66·1-99·8; 13 of 14), and 60% (32·2-83·7, nine of 15) and GMTs of 511·5 (177·6-1473·6), 174·2 (51·6-587·6), and 79 (19·0-326·8) in the flavivirus naive, Japanese encephalitis vaccine-primed, and yellow fever vaccine-primed groups, respectively. INTERPRETATION: We found ZPIV to be well tolerated in flavivirus naive and primed adults but that immunogenicity varied significantly according to antecedent flavivirus vaccination status. Immune bias towards the flavivirus antigen of initial exposure and the timing of vaccination may have impacted responses. A third ZPIV dose overcame much, but not all, of the discrepancy in immunogenicity. The results of this phase 1 clinical trial have implications for further evaluation of ZPIV's immunisation schedule and use of concomitant vaccinations. FUNDING: Department of Defense, Defense Health Agency; National Institute of Allergy and Infectious Diseases; and Division of Microbiology and Infectious Disease.
引用
- Koren MA, Lin L, Eckels KH, et al. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial. Lancet Infect Dis. 2023. PMID: 37390836. doi:10.1016/S1473-3099(23)00192-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。